A biocompatible nanoformulation combining IR820 and FITC within glycol chitosan-coated PCL nanoparticles enables image-guided cancer therapy and diagnostics. The technology leverages laser-activated photothermal action along with sustained fluorescence for effective treatment and monitoring.
Figure (1) In situ conjugation/encapsulation of FITC; (2) Ex situ conjugation of FITC on prepared nanoparticles
Current photothermal therapy agents face limitations such as high cost, poor water solubility, low physiological stability, and loss of imaging functionality post-therapy. These drawbacks reduce the efficacy of cancer diagnostics and treatment.
- Biocompatibility and Stability: The nanoparticles are biocompatible, retain fluorescence and 3D structure after laser exposure, and remain stable in aqueous media.
- Apoptotic and Imaging Dual Action: They induce both apoptotic and necrotic cell death while enabling continued imaging after treatment.
- Poloxamer-Enhanced Immunotherapy: Poloxamer improves immune response and helps overcome multidrug resistance in cancer therapy.
- Ex Situ and In Situ FITC Conjugation: FITC can be conjugated during or after nanoparticle synthesis, offering flexibility in preparation.
A working prototype includes FITC and IR820 co-loaded nanoparticles formed via oil-in-water emulsion and ex/in situ conjugation. It has been characterized by SEM, TEM, AFM, DLS, UV-vis, XRD, DSC, and LC-MS.
This technology is developed at laboratory scale and tested for cancer therapy and imaging.
2
The technology offers an affordable, biocompatible, and biodegradable alternative to existing photothermal agents, potentially improving early cancer diagnosis, treatment response tracking, and reducing recurrence rates. It is especially relevant for drug-resistant and difficult-to-treat cancers.
- Cancer Theranostics: Integrated therapy and diagnostics for various cancer types
- Biomedical Imaging: Long-lasting fluorescence for in vivo tracking
- Photothermal & Immunotherapy: Effective against drug-resistant tumors
- Drug Delivery Systems: Amphiphilic design allows controlled delivery of diverse drugs
Geography of IP
Type of IP
201621024204
389292